Arch Biopartners' AB569 Receives Final Approval from

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Arch Biopartners' AB569 Receives Final Approval from European Commission for Orphan Designation for Cystic Fibrosis

TORONTO, ONTARIO--(Marketwired - June 1, 2016) - Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced the European Commission has designated AB569 as an orphan medicinal product in the European Union for the treatment of patients with cystic fibrosis (CF).

The orphan medicinal products designation is for the two active ingredients of AB569, sodium nitrite ethylenediaminetetraacetic acid (EDTA). AB569 was developed to treat antibiotic resistant bacterial infections, which is a significant problem in the lungs of most adult CF patients.

About Arch Biopartners

Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.

Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; MetaMx, which targets illusive brain tumor initiating cells; and, Metablok, a potential treatment for sepsis and cancer metastasis.

For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com

The Company has 53,189,679 common shares outstanding.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Arch Biopartners Inc. Richard Muruve Chief Executive Officer 647-428-7031 info@archbiopartners.com www.archbiopartners.com Virtus Advisory Group Inc. Babak Pedram Investor Relations 416-644-5081 bpedram@virtusadvisory.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 7

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 19

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 42

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 114

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 91

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 136

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading

Top 5 Most Recently Viewed Articles

Moatable, Inc. Concludes the Tender Offer for Class A Shares

Updated Category News Views 139

Moatable, Inc. Completes Tender Offer for Class A Shares Moatable, Inc. (Pink Limited Market: MTBLY), a premier US-based SaaS company, has announced the successful completion of its fixed price tender offer. The company aimed to repurchase an impressive 225 million Class A ordinary shares. Each share has a par value of $0.001, and they can also be represented by American...

Continue Reading
Armstrong World Industries' Q4 Earnings: What Investors Need

Updated Category News Views 164

Armstrong World Industries Q4 Earnings Report Let’s dive right into this latest earnings report from Armstrong World Indus (NYSE:AWI) that just hit the streets. Released on February 24, 2026, bright and early, it’s got both good news and some not-so-great tidbits that every investor should chew on. Honestly, missing earnings estimates by a margin like -3.59% just...

Continue Reading
Batteries Plus Enhances Partnership for Educational Safety Needs

Updated Category News Views 254

Batteries Plus Enhances Partnership for Educational Safety Needs From Campus Fleets to Classroom Security, Local Teams Support Operational Readiness for Schools and Universities Nationwide Batteries Plus is deepening its partnerships with K-12 districts, colleges, and universities by supplying a broad range of comprehensive battery, lighting, and security system support....

Continue Reading
Exciting Developments in Houston: The RO Project Advances

Updated Category News Views 453

Transwestern Launches Next Phase of The RO Development Transwestern, a prominent commercial real estate firm headquartered in Houston, has taken a monumental step forward by breaking ground on the next phase of The RO. This innovative project aims to redefine the River Oaks neighborhood, representing a significant addition to the area that harmonizes various aspects of...

Continue Reading
BMO Financial Group Plans Large Share Repurchase Initiative

Updated Category News Views 95

BMO Financial Group's Strategic Share Buyback Program Bank of Montreal (TSX:BMO)(NYSE:BMO) has announced an ambitious plan to repurchase up to 20 million common shares through a normal course issuer bid. This initiative is designed to strengthen the bank's capital structure and reflects its confidence in its business fundamentals. Details of the Share Repurchase Plan The...

Continue Reading